PAM
GNMX

Panagora Asset Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Panagora Asset Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-19,860
Closed -$14K – 2628
2018
Q4 		$14K Sell
19,860
-40,316
-67% -$45K ﹤0.01% 2289
2018
Q3 		$74K Sell
60,176
-17,056
-22% -$19.1K ﹤0.01% 1935
2018
Q2 		$86K Buy
77,232
+15,072
+24% +$22.9K ﹤0.01% 1889
2018
Q1 		$125K Sell
62,160
-1,799
-3% -$3.38K ﹤0.01% 1801
2017
Q4 		$77K Buy
63,959
+5,433
+9% +$7.42K ﹤0.01% 1958
2017
Q3 		$74K Buy
+58,526
New +$74.8K ﹤0.01% 1971

Other funds holding GNMX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Panagora Asset Management's GNMX Position: Q1 2019 in Review

Panagora Asset Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2019, closing a stake of 19,860 shares — an estimated $14K sold.

Panagora Asset Management first reported a position in GNMX in Q3 2017 and held it in 6 quarters. The position peaked at $125K in Q1 2018. 28 funds tracked by Wall St. Rank hold GNMX as of Q1 2019.

  • Panagora Asset Management reported no remaining Aevi Genomic Medicine Inc position as of Q1 2019 after selling out during the quarter.
  • Panagora Asset Management sold 19,860 Aevi Genomic Medicine Inc shares in Q1 2019, an estimated $14K.
  • Panagora Asset Management first reported a position in Aevi Genomic Medicine Inc in Q3 2017 and held it in 6 quarters.
  • Panagora Asset Management's Aevi Genomic Medicine Inc position peaked at $125K in Q1 2018.
  • 28 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2019.

Based on Panagora Asset Management's 13F filing for Q1 2019, filed 15 May 2019.